Pharmaceutical Drug Fast-Tracked for Malaria Prevention

A pharmaceuticals company has received fast-track designation from the U.S. Food and Drug Administration for the production of a drug that could possibly prevent malaria in adults.

In December, 60 Degrees Pharmaceuticals submitted a new drug application (NDA) for the use of Tafenoquine to prevent malaria in adults traveling to areas where the disease remains prevalent.

Malaria, a life-threatening disease transmitted through the bite of an infected mosquito, caused an estimated 429,000 fatalities and 212 million clinical cases in 2015.

The pharmaceutical company contends the disease poses a significant risk to millions of healthy individuals traveling in many parts of the world, including employees of nongovernmental organizations, casual vacationers, industrial and business workers, and military forces.

Malaria cases among travelers returning to the U.S. have been trending upwards, with 84 percent of those infected requiring hospitalization, the company said.

The company entered into a cooperative research and development agreement with the U.S. Army Medical Materiel Development Activity in 2014 to develop Tafenoquine as a weekly prophylactic drug for the prevention of malaria.

A drug is designated as a fast-track product “for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition,” according to the FDA.

Since malaria is the top infectious disease threat to service members overseas, the U.S. military maintains a anti-malarial drug development effort through internal research and commercial partnerships.

The NDA submission is a culmination of over 30 years of research and development with the U.S. Army Medical Research and Materiel Command.

A recent analysis of five clinical trials to assess the safety and tolerability of Tafenoquine has been published in Travel Medicine and Infectious Disease, a peer-reviewed journal.

The authors concluded that Tafenoquine appeared to be safe and well tolerated when the anticipated clinical regimen (ACR) was administered.

“Finding acceptable drugs to safeguard travelers and deployed military personnel against malaria is a real problem,” said Geoffrey Dow, CEO of 60 Degrees. “We see Fast Track Designation as a next step toward marketing this product with a convenient weekly dosing regimen in the United States, and eventually around the world. It is our continued belief our dossier will receive priority review, thereby expediting the review of Tafenoquine.”

Show More

Sarafina Wright –Washington Informer Staff Writer

Sarafina Wright is a staff writer at the Washington Informer where she covers business, community events, education, health and politics. She also serves as the editor-in-chief of the WI Bridge, the Informer’s millennial publication. A native of Charlotte, North Carolina, she attended Howard University, receiving a Bachelor of Arts in Journalism. A proud southern girl, her lineage can be traced to the Gullah people inhabiting the low-country of South Carolina. The history of the Gullah people and the Geechee Dialect can be found on the top floor of the National Museum of African American History and Culture. In her spare time she enjoys watching either college football or the Food Channel and experimenting with make-up. When she’s not writing professionally she can be found blogging at E-mail: Social Media Handles: Twitter: @dreamersexpress, Instagram: @Sarafinasaid, Snapchat: @Sarafinasaid

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker